Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,637 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial.
Topalian SL, Bhatia S, Amin A, Kudchadkar RR, Sharfman WH, Lebbé C, Delord JP, Dunn LA, Shinohara MM, Kulikauskas R, Chung CH, Martens UM, Ferris RL, Stein JE, Engle EL, Devriese LA, Lao CD, Gu J, Li B, Chen T, Barrows A, Horvath A, Taube JM, Nghiem P. Topalian SL, et al. Among authors: gu j. J Clin Oncol. 2020 Aug 1;38(22):2476-2487. doi: 10.1200/JCO.20.00201. Epub 2020 Apr 23. J Clin Oncol. 2020. PMID: 32324435 Free PMC article. Clinical Trial.
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.
Naumann RW, Hollebecque A, Meyer T, Devlin MJ, Oaknin A, Kerger J, López-Picazo JM, Machiels JP, Delord JP, Evans TRJ, Boni V, Calvo E, Topalian SL, Chen T, Soumaoro I, Li B, Gu J, Zwirtes R, Moore KN. Naumann RW, et al. Among authors: gu j. J Clin Oncol. 2019 Nov 1;37(31):2825-2834. doi: 10.1200/JCO.19.00739. Epub 2019 Sep 5. J Clin Oncol. 2019. PMID: 31487218 Free PMC article. Clinical Trial.
Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors.
Vieito M, Moreno V, Spreafico A, Brana I, Wang JS, Preis M, Hernández T, Genta S, Hansen AR, Doger B, Galvao V, Lenox L, Brown RJ, Kalota A, Mehta J, Pastore F, Patel B, Mistry P, Gu J, Lauring J, Patel MR. Vieito M, et al. Among authors: gu j. Clin Cancer Res. 2023 Sep 15;29(18):3592-3602. doi: 10.1158/1078-0432.CCR-23-0092. Clin Cancer Res. 2023. PMID: 37491846 Clinical Trial.
Targeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer models.
Li D, Geng K, Hao Y, Gu J, Kumar S, Olson AT, Kuismi CC, Kim HM, Pan Y, Sherman F, Williams AM, Li Y, Li F, Chen T, Thakurdin C, Ranieri M, Meynardie M, Levin DS, Stephens J, Chafitz A, Chen J, Donald-Paladino MS, Powell JM, Zhang ZY, Chen W, Ploszaj M, Han H, Gu S, Zhang T, Hu B, Nacev BA, Kaiza ME, Berger AH, Wang X, Li J, Sun X, Liu Y, Zhang X, Bruno TC, Gray NS, Nabet B, Wong KK, Zhang H. Li D, et al. Among authors: gu j. J Clin Invest. 2024 Dec 24:e174249. doi: 10.1172/JCI174249. Online ahead of print. J Clin Invest. 2024. PMID: 39718828 Free article.
12,637 results
You have reached the last available page of results. Please see the User Guide for more information.